標(biāo)題: Titlebook: Genomic Applications in Pathology; George Jabboure Netto,Iris Schrijver Book 20151st edition Springer Science+Business Media New York 2015 [打印本頁(yè)] 作者: Levelheaded 時(shí)間: 2025-3-21 18:13
書目名稱Genomic Applications in Pathology影響因子(影響力)
書目名稱Genomic Applications in Pathology影響因子(影響力)學(xué)科排名
書目名稱Genomic Applications in Pathology網(wǎng)絡(luò)公開(kāi)度
書目名稱Genomic Applications in Pathology網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書目名稱Genomic Applications in Pathology被引頻次
書目名稱Genomic Applications in Pathology被引頻次學(xué)科排名
書目名稱Genomic Applications in Pathology年度引用
書目名稱Genomic Applications in Pathology年度引用學(xué)科排名
書目名稱Genomic Applications in Pathology讀者反饋
書目名稱Genomic Applications in Pathology讀者反饋學(xué)科排名
作者: crescendo 時(shí)間: 2025-3-21 22:50 作者: falsehood 時(shí)間: 2025-3-22 04:01
Service Policy and Development,hanging discoveries; and discuss the potential impact of genomic biomarkers on the design of new clinical trials. Finally, we review current guidelines and recommendations for moving a successful biomarker from the pathology research laboratory into clinical practice.作者: 是限制 時(shí)間: 2025-3-22 08:28
Food Security and African Development, (WGS)..Every laboratory adopting NGS has undergone two learning curves, one regarding the implementation of new chemistries and instrumentation and the second being the acquisition of the knowledge and skill sets necessary for the analysis of NGS data. The latter curve has proven to be a significan作者: 生命 時(shí)間: 2025-3-22 11:24 作者: 狗舍 時(shí)間: 2025-3-22 13:06 作者: 狗舍 時(shí)間: 2025-3-22 19:37
Book 20151st editiond the required bioinformatics approaches to analyses of the daunting amount of data generated by current and emerging genomic technologies. Implementation roadmaps for various clinical assays such as single gene, gene panels, whole exome and whole genome assays are discussed together with issues rel作者: 定點(diǎn) 時(shí)間: 2025-3-22 21:45 作者: legislate 時(shí)間: 2025-3-23 01:36 作者: 繁榮中國(guó) 時(shí)間: 2025-3-23 07:06
Fabiana Sciarelli,Azzurra Rinaldierstanding of cancer progression, the effects of therapy, and the identification of novel therapeutic targets. CTC evaluation is expected to become more widely used in both clinical and research settings.作者: flavonoids 時(shí)間: 2025-3-23 12:58
Kenya: Strategies for Development,ratories which are already using this technology currently apply existing clinical laboratory regulations to this novel category of high-complexity testing. Nevertheless, NGS technology holds great promise for the future despite some currently perceived barriers to implementation.作者: Tartar 時(shí)間: 2025-3-23 15:38 作者: 六邊形 時(shí)間: 2025-3-23 18:12 作者: hair-bulb 時(shí)間: 2025-3-23 22:52
Current Massively Parallel Sequencing Technologies: Platforms and Reporting Considerations all the coding regions of the genome (the exome), or of the whole genome itself in the clinical setting. This chapter reviews the major NGS platforms currently in use, as well as the interpretive and ethical challenges involved in filtering through the countless sequence variants observed to generate a meaningful clinical report.作者: albuminuria 時(shí)間: 2025-3-24 05:10
Emerging Next-Generation Sequencing Technologiesenges facing the development of new sequencing technologies. This chapter provides a broad overview of emerging new sequencing technologies including single-molecule and nanopore approaches. Potential applications in nucleic acid analysis which will be enabled by these technological advances are also highlighted.作者: 使殘廢 時(shí)間: 2025-3-24 09:25
Circulating Tumor Cells: Enrichment and Genomic Applicationserstanding of cancer progression, the effects of therapy, and the identification of novel therapeutic targets. CTC evaluation is expected to become more widely used in both clinical and research settings.作者: Nonporous 時(shí)間: 2025-3-24 10:56
Implementation of Genome Sequencing Assaysratories which are already using this technology currently apply existing clinical laboratory regulations to this novel category of high-complexity testing. Nevertheless, NGS technology holds great promise for the future despite some currently perceived barriers to implementation.作者: 都相信我的話 時(shí)間: 2025-3-24 16:58 作者: 小淡水魚 時(shí)間: 2025-3-24 19:02 作者: 泛濫 時(shí)間: 2025-3-25 02:13 作者: 挖掘 時(shí)間: 2025-3-25 06:19 作者: 擁護(hù) 時(shí)間: 2025-3-25 08:54
Futures—and Still More Complexitye. In this chapter, we review the history of circulating DNA, technologies for identifying and measuring circulating DNA, and newer applications that are promising to become new standards of care for clinical medicine.作者: opalescence 時(shí)間: 2025-3-25 11:52 作者: 散開(kāi) 時(shí)間: 2025-3-25 16:07
https://doi.org/10.1007/978-3-030-91131-7r high-throughput sequencing can be applied to single-gene targets in specialized situations. This chapter discusses these applications in minimal residual disease detection, infectious diseases, and HLA typing, among others.作者: Neonatal 時(shí)間: 2025-3-25 20:10 作者: deficiency 時(shí)間: 2025-3-26 00:08
MiRNA Expression Assaysamples, taking into account advantages and disadvantages of each approach. Furthermore, we discuss the diagnostic and therapeutic efficacy of miRNAs as well as their future roles in personalized medicine. This complete picture can help pathologists combine new methods and classical ones for diagnostic and therapeutic purposes.作者: Lipoma 時(shí)間: 2025-3-26 04:21
Circulating Cell-Free DNA for Molecular Diagnostics and Therapeutic Monitoringe. In this chapter, we review the history of circulating DNA, technologies for identifying and measuring circulating DNA, and newer applications that are promising to become new standards of care for clinical medicine.作者: 包租車船 時(shí)間: 2025-3-26 11:17
Regulatory and Reimbursement Issues in Genomic Testings. The value of existing concepts of laboratory developed tests and companion diagnostics will need revision in order to accommodate genomic sequencing assays. This chapter addresses these issues and the notion that, to some extent, these novel technologies will challenge established definitions of disease, and the foundations of medical practice.作者: adulterant 時(shí)間: 2025-3-26 14:50 作者: JAMB 時(shí)間: 2025-3-26 17:20
Next-Generation Sequencing for Gene Panelsy increasing the productivity of individual laboratories. Improved efficiency of molecular genetic testing, driven by the development and implementation of comprehensive disease-targeted gene panels, is propelling the advancement of genomic medicine.作者: 埋葬 時(shí)間: 2025-3-26 22:20 作者: Campaign 時(shí)間: 2025-3-27 02:28 作者: 寡頭政治 時(shí)間: 2025-3-27 08:10
Transcriptome Sequencing (RNA-Seq)ls and tissues and is allowing us to better understand alternative splicing and the functional elements of the genome, and to identify new fusion transcripts in cancer. We also review research and potential clinical applications of RNA-Seq technology in inherited, chronic, neoplastic, and infectious diseases.作者: Catheter 時(shí)間: 2025-3-27 10:04
Patents and Proprietary Assaysions in human genes and genotype–phenotype relationships, and will help facilitate the introduction of large-scale sequencing into clinical practice. The Supreme Court has thereby encouraged the advancement, development, and implementation of personalized medicine.作者: 平息 時(shí)間: 2025-3-27 17:17
https://doi.org/10.1007/978-1-4939-0727-4Circulating Tumor Cells; Clinical Genomics; Genomic Medicine; Pharmacogenomics; RNAseq; Sequencing Assays作者: 松雞 時(shí)間: 2025-3-27 18:45 作者: BLUSH 時(shí)間: 2025-3-28 00:03
Amine Habte,Kobus Visser,Matthew Kofi Ocrany number variation, inversions, chromosomal rearrangements], epigenomic, and transcriptional. Long read lengths are required to enable efficient genomic assembly and accurate phasing, and the detection method must produce highly accurate base calls to minimize errors and reduce costly iterative sequ作者: 故意釣到白楊 時(shí)間: 2025-3-28 04:16 作者: 發(fā)電機(jī) 時(shí)間: 2025-3-28 08:49
https://doi.org/10.1057/9781137463661athological processes. In this chapter, we provide an overview of several of the most recently developed assays, methods, and technologies used to identify, characterize, and confirm miRNA expression in human pathologies. We also outline principal workflows for different preparations of biological s作者: 壁畫 時(shí)間: 2025-3-28 12:53 作者: Feigned 時(shí)間: 2025-3-28 16:18 作者: Glossy 時(shí)間: 2025-3-28 20:33
Piyush Tiwari,Jyoti Rao,Jennifer Daye testing, let alone genomic analysis. Pathologists, given their background in molecular diagnostics and experience directing clinical laboratories, must play a major role in translating genomic technology to patient care. This chapter reviews the significant progress that the pathology community ha作者: 凌辱 時(shí)間: 2025-3-28 23:21 作者: Gnrh670 時(shí)間: 2025-3-29 04:13 作者: happiness 時(shí)間: 2025-3-29 09:26
Wang-Taek Jun,Renee Prendergastuction of novel diagnostic tests. Opponents argue that patents are unnecessary for discovery, and that they raise costs, decrease patient access, and harm innovation in the field of molecular pathology. In two recent Supreme Court cases, . and ., the Court ruled that biological correlations and huma作者: 泥沼 時(shí)間: 2025-3-29 11:39 作者: 犬儒主義者 時(shí)間: 2025-3-29 19:14
Service Policy and Development,ings essential for the use of novel classes of targeting therapies. Although there is considerable enthusiasm for the use of the discoveries of cancer genomics for personalized medicine in clinical practice, the number of new classes of biomarkers incorporated into cancer diagnosis and treatment rem作者: medium 時(shí)間: 2025-3-29 20:14 作者: 否決 時(shí)間: 2025-3-30 00:22
https://doi.org/10.1007/978-3-030-91131-7xpensive to perform analysis on more than a few exons or genes at a time. The nature of high-throughput sequencing has altered these calculations, and large panels of potentially pathogenic genes or even whole exomes or genomes are sequenced routinely. However, the techniques and equipment useful fo作者: 疲憊的老馬 時(shí)間: 2025-3-30 04:32
Drawing the Evaluation Together,lel sequencing technologies. NGS has dramatically expanded the capabilities of laboratories by multiplexing and streamlining DNA sequencing workflows. Replacing traditional target amplification techniques with in-solution enrichment technologies has simplified sequencing template preparation, greatl作者: AFFIX 時(shí)間: 2025-3-30 11:01
https://doi.org/10.1007/978-1-349-26567-1f NGS platforms has made whole-exome sequencing (WES) possible, leading to tremendous improvements in the technology, throughput, cost, and efficiency of variant detection and disease diagnosis. This in turn has brought a paradigm shift in clinical and medical genetics. WES and whole-genome sequenci作者: chalice 時(shí)間: 2025-3-30 15:41
Piyush Tiwari,Jyoti Rao,Jennifer Daye testing, let alone genomic analysis. Pathologists, given their background in molecular diagnostics and experience directing clinical laboratories, must play a major role in translating genomic technology to patient care. This chapter reviews the significant progress that the pathology community has made in genomic medicine training.作者: Legion 時(shí)間: 2025-3-30 19:56 作者: RADE 時(shí)間: 2025-3-30 23:16 作者: 腐爛 時(shí)間: 2025-3-31 00:53
978-1-4939-4647-1Springer Science+Business Media New York 2015作者: 傳授知識(shí) 時(shí)間: 2025-3-31 08:54
Current Massively Parallel Sequencing Technologies: Platforms and Reporting Considerations150–200 bp) DNA region at a time, using a specific pair of complementary primers targeted to just that area of interest, the new sequencing platforms utilize a shotgun approach, randomly shearing the entire genome into over 300 million small fragments, sequencing each of them repeatedly in parallel,作者: ARENA 時(shí)間: 2025-3-31 09:17 作者: 抓住他投降 時(shí)間: 2025-3-31 16:06 作者: 舊石器 時(shí)間: 2025-3-31 21:28
